Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization

Journal of Infectious Diseases

Volumn 213, Issue 6, 2016, Pages 975-984

  Wang, Chunling ^a   Katzelnick, Leah C ^a,b   Montoya, Magelda ^a   Hue, Kien Duong Thi ^c,d   Simmons, Cameron P ^c,d,e   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cambodia; dengue virus; envelope protein; evolution; fitness; genotype; lineage; neutralizing antibodies; Vietnam

Indexed keywords

GLYCOPROTEIN E; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; GENOTYPE; HUMAN; HUMAN CELL; NICARAGUAN; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; VIETNAMESE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; AMINO ACID SUBSTITUTION; BLOOD; CLASSIFICATION; DENGUE VIRUS; EVOLUTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; MOLECULAR EVOLUTION; PHYSIOLOGY; SEROTYPING; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIOLOGICAL EVOLUTION; CLONING, MOLECULAR; DENGUE; DENGUE VIRUS; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION, VIRAL; HUMANS; PHYLOGENY; SEROTYPING; VIRAL ENVELOPE PROTEINS;

EID: 84964799152     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv536     Document Type: Article

References (48)

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
2. Holmes EC, Twiddy SS. The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 2003; 3:19-28.
3. Messina JP, Brady OJ, Scott TW, et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol 2014; 22:138-46.
4. Kochel TJ, Watts DM, Halstead SB, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002; 360:310-2.
5. Zhang C, Mammen MP Jr, Chinnawirotpisan P, et al. Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence. J Virol 2005; 79:15123-30.
6. Adams B, Holmes EC, Zhang C, et al. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A 2006; 103:14234-9.
7. Oh Ainle M, Balmaseda A, Macalalad AR, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med 2011; 3:114ra28.
8. Cummings DA, Irizarry RA, Huang NE, et al. Travelling waves in the occurrence of dengue haemorrhagic fever in Thailand. Nature 2004; 427:344-7.
9. Sittisombut N, Sistayanarain A, Cardosa MJ, et al. Possible occurrence of a genetic bottleneck in dengue serotype 2 viruses between the 1980 and 1987 epidemic seasons in Bangkok, Thailand. Am J Trop Med Hyg 1997; 57:100-8.
10. Wittke V, Robb TE, Thu HM, et al. Extinction and rapid emergence of strains of dengue 3 virus during an interepidemic period. Virology 2002; 301:148-56.
11. Klungthong C, Zhang C, Mammen MP Jr, Ubol S, Holmes EC. The molecular epidemiology of dengue virus serotype 4 in Bangkok, Thailand. Virology 2004; 329:168-79.
12. Thu HM, Lowry K, Myint TT, et al. Myanmar dengue outbreak associated with displacement of serotypes 2, 3, and 4 by dengue 1. Emerg Infect Dis 2004; 10:593-7.
13. Ty Hang VT, Holmes EC, Duong V, et al. Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia. PLoS Negl Trop Dis 2010; 4:e757.
14. Foster JE, Bennett SN, Carrington CV, Vaughan H, McMillan WO. Phylogeography and molecular evolution of dengue 2 in the Caribbean basin, 1981-2000. Virology 2004; 324:48-59.
15. A-Nuegoonpipat A, Berlioz-Arthaud A, Chow V, et al. Sustained transmission of dengue virus type 1 in the Pacific due to repeated introductions of different Asian strains. Virology 2004; 329:505-12.
16. Hay SI, Myers MF, Burke DS, et al. Etiology of interepidemic periods of mosquitoborne disease. Proc Natl Acad Sci U S A 2000; 97:9335-9.
17. Quiner CA, Parameswaran P, Ciota AT, et al. Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua. J Virol 2014; 88:13125-34.
18. Messer WB, Yount B, Hacker KE, et al. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis 2012; 6:e1486.
19. Ferguson N, Anderson R, Gupta S. The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Proc Natl Acad Sci U S A 1999; 96:790-4.
20. Cummings DA, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci U S A 2005; 102:15259-64.
21. Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108:717-25.
22. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995; 375:291-8.
23. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271-83.
24. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012; 109:7439-44.
25. Fibriansah G, Tan JL, Smith SA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 2015; 6:6341.
26. Fibriansah G, Ibarra KD, Ng TS, et al. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 2015; 349:88-91.
27. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 2015; 520:109-13.
28. Brien JD, Austin SK, Sukupolvi-Petty S, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 2010; 84:10630-43.
29. Smith SA, de Alwis AR, Kose N, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 2013; 4: e00873-13.
30. Lai CY, Williams KL, Wu YC, et al. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 2013; 7:e2451.
31. Van Blargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 2013; 9: e1003761.
32. Shrestha B, Brien JD, Sukupolvi-Petty S, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010; 6:e1000823.
33. Kochel TJ, Watts DM, Gozalo AS, Ewing DF, Porter KR, Russell KL. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J Infect Dis 2005; 191:1000-4.
34. Katzelnick LC, Fonville JM, Gromowski GD, et al. Dengue viruses cluster antigenically but not as discrete serotypes. Science 2015; 349:1338-43.
35. Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC. Temperaturedependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 2008; 381:67-74.
36. Kuan G, Gordon A, Aviles W, et al. The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol 2009; 170:120-9.
37. Nguyet MN, Duong TH, Trung VT, et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A 2013; 110:9072-7.
38. Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013; 7:e2357.
39. Pierson TC, Sanchez MD, Puffer BA, et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 2006; 346:53-65.
40. Mattia K, Puffer BA, Williams KL, et al. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One 2011; 6:e27252.
41. Sukupolvi-Petty S, Austin SK, Engle M, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 2010; 84:9227-39.
42. Thomas SJ, Nisalak A, Anderson KB, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg 2009; 81:825-33.
43. Gordon A, Kuan G, Mercado JC, et al. The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis 2013; 7:e2462.
44. Balmaseda A, Standish K, Mercado JC, et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 2010; 201:5-14.
45. Fibriansah G, Ng TS, Kostyuchenko VA, et al. Structural changes in dengue virus when exposed to a temperature of 37 degrees C. J Virol 2013; 87:7585-92.
46. Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 2012; 4:139ra83.
47. Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol 2014; 88:11726-37.
48. Oh Ainle M, Harris E. Dengue pathogenesis: viral factors. In: Gubler DJ, Ooi EE, Vasudevan S, Farrar J, eds. Dengue and dengue hemorrhagic fever. 2nd ed. Wallingford, UK: CABI, 2014:231-50.